DE69617440T2 - Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen - Google Patents

Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Info

Publication number
DE69617440T2
DE69617440T2 DE69617440T DE69617440T DE69617440T2 DE 69617440 T2 DE69617440 T2 DE 69617440T2 DE 69617440 T DE69617440 T DE 69617440T DE 69617440 T DE69617440 T DE 69617440T DE 69617440 T2 DE69617440 T2 DE 69617440T2
Authority
DE
Germany
Prior art keywords
molecules
nucleic acid
acid molecules
hla
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69617440T
Other languages
English (en)
Other versions
DE69617440D1 (de
Inventor
Yannick Guilloux
Francine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Application granted granted Critical
Publication of DE69617440D1 publication Critical patent/DE69617440D1/de
Publication of DE69617440T2 publication Critical patent/DE69617440T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69617440T 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen Expired - Lifetime DE69617440T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
PCT/US1996/006409 WO1996040039A2 (en) 1995-06-07 1996-05-07 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof

Publications (2)

Publication Number Publication Date
DE69617440D1 DE69617440D1 (de) 2002-01-10
DE69617440T2 true DE69617440T2 (de) 2002-08-08

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617440T Expired - Lifetime DE69617440T2 (de) 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Country Status (12)

Country Link
US (3) US5821122A (de)
EP (1) EP0845032B1 (de)
JP (1) JP3849102B2 (de)
AT (1) ATE209680T1 (de)
AU (1) AU704934B2 (de)
CA (1) CA2223694C (de)
DE (1) DE69617440T2 (de)
DK (1) DK0845032T3 (de)
ES (1) ES2167561T3 (de)
PT (1) PT845032E (de)
WO (1) WO1996040039A2 (de)
ZA (1) ZA963907B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032855A1 (en) 1997-01-27 1998-07-30 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
ATE438409T1 (de) 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6607151B2 (en) * 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
CA2474497C (en) 2002-01-30 2013-12-03 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
JP4976853B2 (ja) * 2003-11-21 2012-07-18 インスティチュート・パスツール ボルデテラ（Ｂｏｒｄｅｔｅｌｌａ）の組換えアデニル酸シクラーゼ毒素は腫瘍抗原に対するＴ細胞応答を誘発する
EP1765858B1 (de) * 2004-06-17 2012-11-21 Mannkind Corporation Epitop-analoga
EP1787124A2 (de) 2004-06-23 2007-05-23 The University Of Texas System Verfahren und zusammensetzungen zur detektion von biologischen molekülen mithilfe eines zwei-partikel-komplexes
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
AU2013273987B2 (en) 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
CN105452483B (zh) 2013-03-15 2019-01-11 适应生物技术公司 复杂基因集合中的独特标记的重排适应性免疫受体基因
US10874621B2 (en) 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
EP3139909A4 (de) 2014-05-09 2018-01-03 Yale University Topische formulierung von hyperverzweigten polyglycerolbeschichteten partikeln
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3512563A1 (de) 2016-09-16 2019-07-24 The Johns Hopkins University Protein-nanocages mit verbesserter schleimpenetration zur gezielten gewebe- und intrazellulären verabreichung
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
WO2018196782A1 (en) 2017-04-27 2018-11-01 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018237109A1 (en) 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
US20230172870A1 (en) 2021-12-08 2023-06-08 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DK1025849T5 (da) * 1992-12-22 2003-02-24 Ludwig Inst Cancer Res Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
AU704934B2 (en) 1999-05-06
CA2223694A1 (en) 1996-12-19
JP3849102B2 (ja) 2006-11-22
CA2223694C (en) 2003-06-24
WO1996040039A2 (en) 1996-12-19
US5958711A (en) 1999-09-28
ES2167561T3 (es) 2002-05-16
US5821122A (en) 1998-10-13
PT845032E (pt) 2002-05-31
AU5676996A (en) 1996-12-30
ATE209680T1 (de) 2001-12-15
EP0845032A4 (de) 2000-05-10
DK0845032T3 (da) 2002-05-06
EP0845032A2 (de) 1998-06-03
JP2001520506A (ja) 2001-10-30
WO1996040039A3 (en) 2000-03-23
EP0845032B1 (de) 2001-11-28
DE69617440D1 (de) 2002-01-10
ZA963907B (en) 1997-03-11
US5886145A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
DE69617440T2 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69433790D1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA66753C2 (en) Immunostimulator and method for its production
CA2213001A1 (en) Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
CA2165435A1 (en) Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH, NEW YORK, N.

8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted